BIBF1000

BIBF1000 is a **small molecule, orally active, triple tyrosine kinase inhibitor** that targets vascular endothelial growth factor receptor (VEGFR), platelet-derived growth factor receptor (PDGFR), and fibroblast growth factor receptor (FGFR)[1][2][3][4]. It blocks signaling by these receptors, leading to inhibition of angiogenesis, fibrogenesis, and reduction of inflammatory and remodeling processes relevant to chronic airway diseases and fibrosis. BIBF1000 is mechanistically similar to nintedanib (BIBF1120), an approved drug for idiopathic pulmonary fibrosis, but BIBF1000 itself is a research compound primarily characterized in preclinical models for anti-remodeling, anti-inflammatory, and anti-fibrotic activities, particularly in asthma and pulmonary arterial hypertension models[1][2][4].